{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"97.5","value":"0.0"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"97.5","value":"0.0"},{"groupId":"OG002","lowerLimit":"0.8","upperLimit":"90.6","value":"33.3"},{"groupId":"OG003","lowerLimit":"0.0","upperLimit":"70.8","value":"0.0"},{"groupId":"OG004","lowerLimit":"0.2","upperLimit":"41.3","value":"9.1"},{"groupId":"OG005","lowerLimit":"0.5","upperLimit":"71.6","value":"20.0"},{"groupId":"OG006","lowerLimit":"0.0","upperLimit":"52.2","value":"0.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"11"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"5"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants with a PR or better. The response in RRMM Cohorts was assessed following IMWG criteria 2016. Per IMWG criteria, PR was defined as ≥50% reduction of serum M-protein plus reduction in 24-h urinary M-protein by ≥90% or to \\<200 mg per 24 h. In addition to these criteria, if present at baseline, a ≥50% reduction in the size (SPD) of soft tissue plasmacytomas was also required.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with RRMM received GEN3014 at a dose of 0.2/0.6 mg/kg by IV infusion in 28-day treatment cycles. Intraparticipant dose escalation was performed in this arm (i.e., dose was escalated from 0.2-0.6 mg/kg).","id":"OG000","title":"RRMM Dose Escalation: GEN3014 0.2/0.6 mg/kg"},{"description":"Participants with RRMM received GEN3014 at a dose of 2 mg/kg by IV infusion in 28-day treatment cycles.","id":"OG001","title":"RRMM Dose Escalation: GEN3014 2 mg/kg"},{"description":"Participants with RRMM received GEN3014 at a dose of 4 mg/kg by IV infusion in 28-day treatment cycles.","id":"OG002","title":"RRMM Dose Escalation: GEN3014 4 mg/kg"},{"description":"Participants with RRMM received GEN3014 at a dose of 8 mg/kg by IV infusion in 28-day treatment cycles.","id":"OG003","title":"RRMM Dose Escalation: GEN3014 8 mg/kg"},{"description":"Participants with RRMM received GEN3014 at a dose of 16 mg/kg by IV infusion in 28-day treatment cycles.","id":"OG004","title":"RRMM Dose Escalation: GEN3014 16 mg/kg"},{"description":"Participants with RRMM received GEN3014 at a dose of 24 mg/kg by IV infusion in 28-day treatment cycles.","id":"OG005","title":"RRMM Dose Escalation: GEN3014 24 mg/kg"},{"description":"Participants with R/R AML received GEN3014 at dose level 1 (low dose) in 28-day treatment cycles.","id":"OG006","title":"R/R AML Dose Escalation: GEN3014 Dose Level 1"}],"paramType":"NUMBER","populationDescription":"Full Analysis set included all enrolled participants who received at least 1 dose of trial drug (GEN3014 or daratumumab SC). Overall number of participants analyzed = participants evaluable for the outcome measure.","reportingStatus":"POSTED","timeFrame":"Up to approximately 4 years 3 months","title":"Dose Escalation: ORR","type":"SECONDARY","unitOfMeasure":"percentage of participants"}